George Siber

Q: What Schools Are Affiliated With George Siber

George Siber is affiliated with the following schools: Washington University in St. Louis, McGill University, Tufts University, Massachusetts Institute of Technology, Johns Hopkins University, Harvard University

George Siber's AcademicInfluence.com Rankings

George Siber

Law

#2799

World Rank

#3482

Historical Rank

Common Law

#150

World Rank

#163

Historical Rank

law Degrees

Download Badge

Why Is George Siber Influential?

(Suggest an Edit or Addition)

According to Wikipedia, George Rainer Siber is a medical researcher and vaccine expert with years of experience in developing numerous vaccines, therapeutic antibodies, and diagnostic agents for infectious diseases. Siber is a former Harvard professor, current adjunct professor at Johns Hopkins University and professor at the University of Massachusetts Medical School, former executive vice president and chief science officer of Wyeth, and advisory committee member of the World Health Organization, US National Institutes of Health, Gates Foundation, and the National Institute of Allergy and Infectious Diseases.

(See a Problem?)

George Siber's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children (2000) (2192)
Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. (2000) (854)
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. (2000) (733)
Adjuvants for human vaccines--current status, problems and future prospects. (1995) (559)
Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial. (1997) (558)
Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. (1980) (462)
Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial (2003) (395)
Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. (2003) (357)
The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. (2000) (351)
Adjuvant properties of aluminum and calcium compounds. (1995) (337)
Recurrent sinopulmonary infection and impaired antibody response to bacterial capsular polysaccharide antigen in children with selective IgG-subclass deficiency. (1985) (320)
Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. (1994) (316)
Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. (2007) (302)
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. (1999) (285)
Crystal structure of an endotoxin‐neutralizing protein from the horseshoe crab, Limulus anti‐LPS factor, at 1.5 A resolution. (1993) (247)
Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children (2001) (226)
Pneumococcal disease: prospects for a new generation of vaccines. (1994) (207)
Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease. (1978) (203)
Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. (2008) (203)
An immunodeficiency characterized by impaired antibody responses to polysaccharides. (1987) (186)
Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine (1995) (167)
How Can Vaccines Contribute to Solving the Antimicrobial Resistance Problem? (2016) (159)
Correlation between G2m(n) immunoglobulin allotype and human antibody response and susceptibility to polysaccharide encapsulated bacteria. (1985) (158)
Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. (2005) (157)
Pharmacokinetics of gentamicin in children and adults. (1975) (147)
Pertussis in Massachusetts, 1981-1991: incidence, serologic diagnosis, and vaccine effectiveness. (1994) (146)
Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. (1994) (120)
Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres (1993) (116)
Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. (2007) (115)
Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation. (1995) (114)
Pulsed controlled-released system for potential use in vaccine delivery. (1996) (112)
Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children. (1990) (107)
Transplacental antibody transfer following maternal immunization with polysaccharide and conjugate Haemophilus influenzae type b vaccines. (1995) (105)
Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay (1992) (99)
Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. (1992) (96)
Interference of immune globulin with measles and rubella immunization. (1993) (96)
Rapid diagnosis of Hemophilus influenzae type b infections by latex particle agglutination and counterimmunoelectrophoresis. (1978) (94)
Biodegradable polymer microspheres as vaccine adjuvants and delivery systems. (1998) (92)
Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia. (1996) (90)
Impaired humoral immunity in treated Hodgkin's disease. (1977) (89)
Enhanced detection with an enzyme-linked immunosorbent assay of candida mannan in antibody-containing serum after heat extraction. (1982) (88)
Pneumococcal vaccines: the impact of conjugate vaccine. (2008) (86)
Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid. (1994) (86)
Standardization of antibody assays for measuring the response to pneumococcal infection and immunization (1989) (85)
Selective defect in the antibody response to Haemophilus influenzae type b in children with recurrent infections and normal serum IgG subclass levels. (1988) (84)
In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. (1996) (83)
Functional characterization of human IgG, IgM, and IgA antibody directed to the capsule of Haemophilus influenzae type b. (1986) (82)
Cross-reactivity of rabbit antibodies to lipopolysaccharides of Escherichia coli J5 and other gram-negative bacteria. (1985) (81)
Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin. (1996) (80)
Efficacy of Heptavalent Conjugate Pneumococcal Vaccine (Wyeth Lederle) in 7,000 Infants and Children: Results of the Northern California Kaiser Permanente Efficacy Trial (1999) (78)
Neutralization of bacterial lipopolysaccharides by human plasma (1985) (76)
Adjuvant properties of non-phospholipid liposomes (Novasomes) in experimental animals for human vaccine antigens. (1996) (66)
Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide (1985) (66)
Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. (1982) (65)
Chronic local tissue reactions, long-term immunogenicity and immunologic priming of mice and guinea pigs to tetanus toxoid encapsulated in biodegradable polymer microspheres composed of poly lactide-co-glycolide polymers. (1997) (62)
Turbidimetric method for quantifying serum inhibition of Limulus amoebocyte lysate (1985) (62)
Effect of polymyxin B on experimental shock from meningococcal and Escherichia coli endotoxins. (1991) (61)
Towards a population-based threshold of protection for COVID-19 vaccines (2021) (61)
Design of a group-randomized Streptococcus pneumoniae vaccine trial. (2001) (61)
Preparation of human hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, and Neisseria meningitidis (1984) (61)
Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock. (1992) (61)
Antibody response to pretreatment immunization and post-treatment boosting with bacterial polysaccharide vaccines in patients with Hodgkin's disease. (1986) (59)
Phycomycotic gangrenous cellulitis. A report of two cases and a review of the literature. (1976) (58)
Increased gastrointestinal absorption of large molecules in patients after 5-fluorouracil therapy for metastatic colon carcinoma. (1980) (58)
Placental and breast transfer of antibodies after maternal immunization with polysaccharide meningococcal vaccine: a randomized, controlled evaluation. (2002) (57)
Simultaneous vitamin A administration at routine immunization contact enhances antibody response to diphtheria vaccine in infants younger than six months. (1999) (54)
Determination of protein loading in biodegradable polymer microspheres containing tetanus toxoid. (1997) (53)
Neutralization and lipoprotein binding of lipopolysaccharides in tolerant rabbit serum. (1986) (53)
Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin. (1999) (52)
Th1-associated immune responses to beta-galactosidase expressed by a replication-defective herpes simplex virus. (1996) (51)
Evaluation of bacterial polysaccharide immune globulin for the treatment or prevention of Haemophilus influenzae type b and pneumococcal disease. (1992) (48)
Neonatal central nervous system infection due to Mycoplasma hominis. (1977) (47)
Fluorescence technique to demonstrate creatine phosphokinase isozymes. (1967) (47)
Antibody response of patients with Hodgkin's disease to protein and polysaccharide antigens. (1981) (46)
Interlaboratory study evaluating quantitation of antibodies to Haemophilus influenzae type b polysaccharide by enzyme-linked immunosorbent assay (1996) (46)
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial (2022) (45)
Prevention of Haemophilus influenzae type b infections in Apache and Navajo children. (1992) (45)
A MULTI-LABORATORY EVALUATION OF AN ENZYME-LINKED IMMUNOASSAY QUANTITATING HUMAN ANTIBODIES TO STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDES (2001) (44)
Identification of novel virus-specific antigens by CD4⁺ and CD8⁺ T cells from asymptomatic HSV-2 seropositive and seronegative donors. (2014) (41)
Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants (2001) (40)
Haemophilus influenzae type b-specific antibody in infants after maternal immunization. (1997) (39)
Efficacy of Human Hyperimmune Globulin in Prevention of Haemophilus influenzae Type b Disease in Infant Rats (1983) (38)
Pertussis toxin enhanced IgG1 and IgE responses to primary tetanus immunization are mediated by interleukin-4 and persist during secondary responses to tetanus alone. (1996) (38)
Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial. (2007) (37)
Strategies for stabilising tetanus toxoid towards the development of a single-dose tetanus vaccine. (1996) (37)
Protective Effects of Pertussis Immunoglobulin (P-IGIV) in the Aerosol Challenge Model (1999) (37)
Comparative analysis of tetanus antitoxin titers of sera from immunized mice and guinea pigs determined by toxin neutralization test and enzyme-linked immunosorbent assay. (1994) (36)
Maternal immunization with the capsular polysaccharide vaccine for Haemophilus influenzae type b. (1992) (35)
Minimum protective serum concentrations of pneumococcal anti-capsular antibodies in infant rats. (1998) (35)
Method for quantitation of IgG subclass antibodies in mouse serum by enzyme-linked immunosorbent assay. (1995) (35)
Evaluation of a commercial latex particle agglutination test for rapid diagnosis of Haemophilus influenzae type b infection. (1982) (35)
Normal IgG and impaired IgM responses to polysaccharide vaccines in asplenic patients. (1999) (33)
Safety and immunogenicity of hydrogen peroxide-inactivated pertussis toxoid in 18-month-old children. (1991) (33)
Use of immune globulins in the prevention and treatment of infections. (1992) (32)
Suitability of the Vero cell method for titration of diphtheria antitoxin in the United States potency test for diphtheria toxoid. (1994) (32)
Failure of prophylactic and therapeutic use of a murine anti-tumor necrosis factor monoclonal antibody in Escherichia coli sepsis in the rabbit. (1995) (31)
Methods for estimating serological correlates of protection. (1997) (31)
Passive immunization against disease due to Haemophilus influenzae type b: concentrations of antibody to capsular polysaccharide in high-risk children. (1986) (31)
IgG subclass antibodies to human cytomegalovirus (CMV) in normal human plasma samples and immune globulins and their neutralizing activities. (1996) (31)
Bacteremias due to Haemophilus influenzae and Streptococcus pneumoniae: their occurrence and course in children with cancer. (1980) (31)
Diphtheria antitoxin levels in US blood and plasma donors. (1996) (31)
The role of adjuvants and delivery systems in modulation of immune response to vaccines. (1996) (30)
Serum anticapsular antibody response in the first week after immunization of adults and infants with the Haemophilus influenzae type b-Neisseria meningitidis outer membrane protein complex conjugate vaccine. (1991) (30)
Differences in the immunogenicity of native and formalinized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs. (1997) (29)
Age-dependent dose response to gentamicin. (1975) (29)
Safety and immunogenicity of heptavalent pneumococcal CRM 197 conjugate vaccine in infants and toddlers (29)
Utility of serum interleukin-6 for diagnosis of invasive bacterial disease in children. (1992) (28)
Use of trimethoprim‐sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia (1985) (27)
Development of a model of low-inoculum Streptococcus pneumoniae intrapulmonary infection in infant rats (1997) (27)
High-performance liquid chromatographic quantitation of trimethoprim, sulfamethoxazole, and N4-acetylsulfamethoxazole in body fluids. (1983) (26)
Comparison of active and combined passive/ active immunization of Navajo children against Haemophilus influenzae type b (1988) (26)
Predictability of peak serum gentamicin concentration with dosage based on body surface area. (1979) (26)
Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines. (1995) (26)
Decline of Haemophilus influenzae type b disease in a region of high risk: impact of passive and active immunization. (1994) (25)
Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1 ×, 2 ×, or 4 ×) in healthy subjects aged 70 years or older. (2011) (24)
A simple and rapid method for measuring unconjugated capsular polysaccharide (PRP) of Haemophilus influenzae type b in PRP-tetanus toxoid conjugate vaccine. (1998) (24)
Correlation of the Km(1) immunoglobulin allotype with anti-polysaccharide antibodies in Caucasian adults. (1986) (24)
Pneumococcal vaccine failure. (1981) (24)
Endotoxin neutralization with rabbit antisera to Escherichia coli J5 and other gram-negative bacteria (1987) (23)
PCPP as a parenteral adjuvant for diverse antigens. (1998) (23)
Clonal characterization of the human IgG antibody repertoire to Haemophilus influenzae type b polysaccharide. V. In vivo expression of individual antibody clones is dependent on Ig CH haplotypes and the categories of antigen. (1993) (22)
Blood-group-A-like substance in a preparation of pneumococcal vaccine. (1982) (21)
Food and Drug Administration Center for Biologics Evaluation and Research SUMMARY MINUTES VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE Meeting # 104: November 16 - 17, 2005 Holiday Inn Select, Bethesda, MD (2005) (21)
Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysaccharide conjugate vaccine. (1999) (21)
Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine (1995) (21)
Comparison of a recombinant endotoxin-neutralizing protein with a human monoclonal antibody to endotoxin for the treatment of Escherichia coli sepsis in rats. (1994) (21)
Advantage of latex agglutination over countercurrent immunoelectrophoresis in the detection of Haemophilus influenzae type b antigen in serum. (1981) (20)
Formation and cell-medium partitioning of autoinhibitory free fatty acids and cyclodextrin's effect in the cultivation of Bordetella pertussis. (1996) (20)
Resolution of Chlamydia trachomatis Infection Is Associated with a Distinct T Cell Response Profile (2015) (20)
Interpretation of IgG subclass values: a comparison of two assays. (1990) (19)
Decreased protective efficacy of reduced and alkylated human immune serum globulin in experimental infection with Haemophilus influenzae type b (1985) (19)
A modified Farr assay is more specific than ELISA for measuring antibodies to Streptococcus pneumoniae capsular polysaccharides. (1996) (19)
Simultaneous administration of vaccines for Haemophilus influenzae type b, pneumococci, and meningococci. (1986) (18)
Graphical method for evaluating antibody response to vaccines (1980) (16)
Recombinant endotoxin neutralizing protein improves survival from Escherichia coli sepsis in rats. (1995) (16)
Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidate (2021) (16)
Ig allotype-linked regulation of class and subclass composition of natural antibodies to group A streptococcal carbohydrate. (1989) (16)
Production of cell mass and pertussis toxin by Bordetella pertussis. (1991) (16)
Comparison of two antigen detection techniques in a primate model of Haemophilus influenzae type b infection (1979) (16)
The V-region repertoire of Haemophilus influenzae type b polysaccharide antibodies induced by immunization of infants (1995) (14)
Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines. (1996) (13)
Efficacy of a recombinant endotoxin neutralizing protein in rabbits with Escherichia coli sepsis. (1994) (13)
Value of antigen quantitation in Haemophilus influenzae type b meningitis. (1984) (13)
EFFECT OF MEMNINGOCOCCAL ENDOTOXIN IN A RABBIT MODEL OF SHOCK (1990) (12)
Evaluation of the Indirect Effects of a Pneumococcal Vaccine in a Community-Randomized Study (2006) (12)
Gentamicin penetration into cerebrospinal fluid in experimental Haemophilus influenzae meningitis (1988) (11)
High-dose recombinant endotoxin neutralizing protein improves survival in rabbits, with Escherichia coli sepsis. (1996) (11)
Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial (2022) (11)
Postvaccination susceptibility to invasive Haemophilus influenzae type b disease in infant rats. (1988) (11)
Inhibition of ATP-induced surfactant exocytosis by dihydropyridine (DHP) derivatives: a non-stereospecific, photoactivated effect and independent of L-type Ca2+ channels. (2001) (11)
Improved pertussis toxin production by Bordetella pertussis through adjusting the growth medium's ionic composition. (1995) (10)
A comparison of bactericidal/permeability-versus increasing protein variant recombinant endotoxin-neutralizing protein for the treatment of Escherichia coli sepsis in rats (1997) (10)
Effect of pertussis toxin on susceptibility of infant rats to Haemophilus influenzae type b. (1992) (10)
DELETERIOUS EFFECT OF IMMUNE GLOBULIN IN THE TREATMENT OF H. INFLUENZAE B INFECTION IN INFANT RATS (1987) (10)
Antibody response of Navajo children primed with PRP‐OMP vaccine to booster doses of PRP‐OMP vs. HbOC vaccine (1993) (10)
An enzyme immunoassay based micro-neutralization test for titration of antibodies to human cytomegalovirus (CMV) and its correlation with direct ELISA measuring CMV IgG antibodies. (1996) (10)
Haemophilus influenzae type b unsuspected bacteremia (1987) (9)
Quantitative Priming with Inactivated Pertussis Toxoid Vaccine in the Aerosol Challenge Model (2002) (9)
Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines (2021) (9)
Contributions of Native Americans to the global control of infectious diseases. (2007) (9)
Stability of trimethoprim-sulfamethoxazole injection in two infusion fluids. (1981) (8)
Moxalactam pharmacokinetics in children (1982) (8)
Effect of complement depletion on anticapsular-antibody-mediated immunity to experimental infection with Haemophilus influenzae type b (1987) (8)
Counterimmunoelectrophoresis for detection of microbial antigens: increased sensitivity with dextran-containing gels (1978) (8)
Development of an animal model to assess the immunogenicity of single-dose tetanus and diphtheria vaccines based on controlled release from biodegradable polymer microspheres. (1998) (8)
Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years. (2022) (8)
Methods for the analysis of antibody responses to vaccines or other immune stimuli. (1983) (7)
Passive immunization for infection with Haemophilus influenzae type b. (1990) (7)
BACTERIAL POLYSACCHARIDE IMMUNE GLOBULIN (BPIG) PROTECTS INFANT RATS WITH S. PNEUMONIAE (SP) PNEUMONIA FROM BACTEREMIA, MENINGITIS AND DEATH. • 1092 (1996) (7)
Comparison of early and late treatment with a recombinant endotoxin neutralizing protein in a rat model of Escherichia coli sepsis. (1996) (7)
Failure of recombinant interleukin-2 to augment the primary humoral response to a recombinant hepatitis B vaccine in healthy adults. (1992) (7)
Endotoxin neutralizing capacity of sera from different patient populations assessed by the Limulus lysate test. (1987) (7)
Association of placental transfer of anti-Haemophilus influenzae type b polysaccharide antibodies with their V regions. (1996) (6)
A Population-Based Threshold of Protection for COVID-19 Vaccines (2021) (6)
1242. Safety and Immunogenicity of Novel 24-Valent Pneumococcal Vaccine in Healthy Adults (2020) (6)
Antibody response of infants to Haemophilus influenzae type b capsular polysaccharide combined with Bordetella pertussis. (1985) (6)
A comparison of bactericidal/permeability-increasing protein variant versus recombinant endotoxin-neutralizing protein for the treatment of Escherichia coli sepsis in rats . (1997) (6)
Inhibition of moisture-induced aggregation of tetanus toxoid by protecting thiol groups (1994) (6)
Reappraisal of existing methods for potency testing of vaccines against tetanus and diphtheria. (1995) (5)
Establishing Immune Correlates of Protection (2008) (5)
Use of in vitro Vero cell assay and ELISA in the United States potency test of vaccines containing adsorbed diphtheria and tetanus toxoids. (1996) (5)
Haemophilus Influenzae type b meningitis after three doses of vaccine (1994) (4)
RAPID DIAGNOSIS OF H. INFLUENZAE TYPE B (HIB) INFECTIONS BY LATEX PARTICLE AGGLUTINATION (LPA) AND COUNTER IMMUNOELECTROPHORESIS (CIE) (1977) (4)
Immunogenicity and Safety in Adults (2008) (4)
κ and λ Light Chain Composition of Antibody to the Capsular Polysaccharide of Haemophilus influenzae Type b (1990) (4)
Need for a reference preparation of pertussis antitoxin for Chinese hamster ovary cell assay. (1995) (4)
Correlations of G2m(n) and Km(1) allotypes with subclass- and light-chain-specific antibody. (1988) (3)
Innovative approaches for the stabilization and controlled release of tetanus vaccine from polyester microspheres (1996) (2)
Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine (2022) (2)
PASSIVE PROTECTION FOR HAEMOPHILUS INFLUENZAE TYPE B (HIB) DISEASE: ANTIBODY LEVELS IN INFANTS GIVEN HYPERIMMUNE GLOBULIN (1984) (2)
COMPARISON OP ANTIGEN DETECTION METHODS IN A PRIMATE MODEL OF HEMOPHILUS MEMINGITIS (1977) (2)
Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & Melinda Gates Foundation workshop held on 10 and 11 February 2021. (2022) (2)
Mechanisms of moisture-induced aggregation of tetanus toxoid (1995) (2)
Kappa and lambda light chain composition of antibody to the capsular polysaccharide of Haemophilus influenzae type b. (1990) (1)
Stability of gentamicin in plastic syringes. (1977) (1)
The treatment of Hodgkin's disease (HD) and humoral immunity (1977) (1)
ENDOTOXIN NEUTRALIZING PROTEIN INHIBITS THE RESPONSE OF HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS TO LPS AND NON-LPS STIMULI. • 1045 (1996) (1)
Interference of immune globulin with measles and rubella immunization. (1993) (1)
Vitamin A administration with immunization enhances antibody response to diphtheria vaccine (1999) (1)
Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study (2023) (1)
Contributors (2008) (0)
SUSCEPTIBILITY TO INVASIVE H. INFLUENZAE (Hi) INFECTION IMMEDIATELY AFTER IMMUNIZATION WITH THE CAPSULAR VACCINE (1987) (0)
HumanAntibody Response totheB Oligomer ofPertussis Toxin (1994) (0)
Table of Contents (1993) (0)
INFANT RAT MODEL OF VACCINE TYPE S. PNEUMONIAE (SP) PNEUMONIA.† 1091 (1996) (0)
Multivalent pneumococcal saccharide-protein conjugate composition (2006) (0)
Mycoplasma hominis infection due to (1977) (0)
The use of intravenous gamma globulin for CMV prophylaxis. (1993) (0)
1146 PNEUMOCOCCAL ANTIGEN DETECTION IN CHILDREN AT RISK FOR OCCULT BACTEREMIA (1985) (0)
conjugate polysaccharide-protein composition pneumococcal multivante (2006) (0)
Composition of a multivalent conjugate pneumococcal polysaccharide-protein (2007) (0)
A RECOMBINANT ENDOTOXIN NEUTRALIZING PROTEIN IMPROVES SURVIVAL IN RABBITS WITH E. COLI SEPSIS (1992) (0)
Community and International Nutrition Simultaneous Vitamin A Administration at Routine Immunization Contact Enhances Antibody Response to Diphtheria Vaccine in Infants Younger than Six Months 1 (1999) (0)
336 Children with IgG2 subclass deficiency have an impaired response to the polyribose phosphate (PRP) polysaccharide vaccine (1985) (0)
AN INFANT RAT MODEL OF STREPTOCOCCUS PNEUMONIAE (SP) NASAL COLONIZATION AND INVASIVE PNEUMOCOCCAL DISEASE. 1054 (1996) (0)
Geographical differences for pneumococcal disease (2001) (0)
BACTERIAL POLYSACCHARIDE IMMUNE GLOBULIN (BPIG) DOES NOT PROTECT INFANT RATS FROM NASAL COLONIZATION WITH STREPTOCOCCUS PNEUMONIAE (SP). • 1055 (1996) (0)
Polymyxin B for experimental shock from meningococcal endotoxin (1989) (0)
Synthesis and Recommendations (2008) (0)
"Vaccines Against Meningococcus" An update of the progresses in meningitis prevention, based on the Meningococcus Scientific Exchange Meeting, Siena, Italy, 1-3 July 2008. (2009) (0)
multivalent composition conjugates of pneumococcal polysaccharide-protein (2007) (0)
Comprar Pneumococcal Vaccines: The Impact of Conjugate Vaccine | Mary Barasi | 9781555814083 | Wiley (2008) (0)
Process for the preparation of immunoglobulin for the treatment of respiratory tract infections caused by viruses (1993) (0)
Comparative evaluation of aluminum phosphate, calcium phosphate, stearyl tyrosine, gamma inulin, conjugation to dextran, liposomes and poly lactide/glycolide microspheres as adjuvants/delivery systems for tetanus and diphtheria toxoids (1994) (0)
Immunogenicity of SCB-2019 COVID-19 Vaccine Compared to Four Approved Vaccines (2021) (0)
Antibody to H. influenzae type B capsular polysaccharide in maternal and cord sera from Inuit, Native Indian and Caucasian subjects in the Northwest Territories and Manitoba. (1991) (0)
COMPARISON OF NATIVE AND REDUCED AND ALKYLATED HUMAN IV IMMUNE SERUM GLOBULIN (ISG) IN EXPERIMENTAL H. IN FLUENZAE TYPE B INFECTION (1984) (0)
A method for the screening of plasma samples for effective antibody titers against viruses respratoriske (1992) (0)
PASSIVE IMMUNIZATION Passive Immunization for Infection With Haemophilus influenzae Type b (2006) (0)
Human antibody response to the B oligomer of pertussis toxin. (1994) (0)
Development of a pneumococcal conjugate vaccine (2001) (0)

This paper list is powered by the following services:

Other Resources About George Siber

en.wikipedia.org

What Schools Are Affiliated With George Siber?

George Siber is affiliated with the following schools:

George Siber's Academic­Influence.com Rankings